Evidence map›Paper›PMID 34227265›Full record

ArticleKorean circulation journal2021

Economic Burden of Heart Failure in Asian Countries with Different Healthcare Systems.

Teerapat Yingchoncharoen, Tao Cheng Wu, Dong Ju Choi, Tiong Kiam Ong, Houng Bang Liew, Myeong Chan Cho

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean circulation journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Heart failure: a prevalence-based and model-based cost analysis.Frontiers in cardiovascular medicine · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Teerapat YingchoncharoenDivision of Cardiology, Department of Internal Medicine, Ramathibodi Hospital, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5689-2704
Tao Cheng WuDivision of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan ROC.ORCID https://orcid.org/0000-0001-6572-8148
Dong Ju ChoiDivision of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID https://orcid.org/0000-0003-0146-2189
Tiong Kiam OngDepartment of Cardiology, Sarawak General Hospital, Kuching, Malaysia.ORCID https://orcid.org/0000-0002-3572-9251
Houng Bang LiewDepartment of Cardiology, Queen Elizabeth Hospital 2, Sabah, Malaysia.ORCID https://orcid.org/0000-0003-1914-3872
Myeong Chan ChoDepartment of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea. mccho@cbnu.ac.kr.ORCID https://orcid.org/0000-0002-0047-0227

Funding

Novartis Pharma AG
6 · The paper itself

Abstract

BACKGROUND AND

objectivesHeart failure (HF) poses substantial economic burden, primarily driven by high hospitalization and mortality rates. This study aimed to understand the economic burden of HF in 4 Asian countries under varying healthcare systems.

methodsThis was a non-interventional, retrospective study conducted in South Korea, Taiwan, Thailand and Malaysia through medical chart review. Eligible patients included those who had either ≥1 hospitalization or ≥2 outpatient visits from January 1st to December 31st, 2014, and at least one year of follow-up. Resource use and direct healthcare costs (adjusted to 2015 USD) of HF were assessed. HF costs for subgroups stratified by age and sex were assessed.

resultsA total of 568 patients were recruited from South Korea (n=200), Taiwan (n=200), Thailand (n=100) and Malaysia (n=68). The proportion of patients hospitalized ranged from 20.0% to 93.5% (South Korea 20.0%, Thailand 49.0%, Malaysia 70.6%, and Taiwan 93.5%). The overall annual HF cost per patient was $2,357, $4,513, $3,513 and $1,443 in South Korea, Taiwan, Thailand, and Malaysia, respectively; hospitalized HF care costs were $10,714, $4,790, $7,181 and $1,776, respectively. The length of stay was more than 12.2 days except in Malaysia. No specific trend was observed in subgroup analysis.

conclusionsIn Asia, HF poses significant economic burden and hospitalization has emerged as the major cost driver among healthcare costs. A streamlined treatment strategy reducing hospitalization rate can minimize the economic burden.

Indexed as

Cost of illnessHealth care costsHeart failureHospitalizationLength of stay

Identifiers

PMID34227265
PMCPMC8326210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.